MeSH Browser

MeSH Heading: Abciximab
Tree Number(s): D12.644.541.500.650.125; D12.776.124.486.485.114.224.060.125; D12.776.124.486.485.680.650.125; D12.776.124.790.651.114.224.060.125; D12.776.124.790.651.680.650.125; D12.776.377.715.548.114.224.200.125; D12.776.377.715.548.680.650.125
Unique ID: D000077284
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D000077284
Scope Note: A Fab fragment of the chimeric monoclonal antibody 7E3 that binds to the glycoprotein IIb-IIIa receptor of human platelets, and blocks PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX, potently inhibiting PLATELET AGGREGATION. It is used in treatment of refractory unstable angina, and for prevention of ischemic complications in patients undergoing percutaneous coronary procedures such as ANGIOPLASTY; ATHERECTOMY; or stenting.
Entry Term(s): CentoRx; Chimeric 7E3 Fab; Clotinab; ReoPro; c7E3 Fab
Pharm Action: Anticoagulants
Platelet Aggregation Inhibitors
Registry Number: X85G7936GV
Related Numbers: 143653-53-6
Public MeSH Note: 2019; ABCIXIMAB was indexed under ANTIBODIES, MONOCLONAL and IMMUNOGLOBULIN FAB FRAGMENTS 1994-2018
History Note: 2019 (1994)
Date Established: 2019/01/01
Date of Entry: 2018/07/09
Revision Date: 2018/02/27

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

analysis (AN)

biosynthesis (BI)

blood (BL)

cerebrospinal fluid (CF)

chemistry (CH)

classification (CL)

drug effects (DE)

economics (EC)

genetics (GE)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

physiology (PH)

poisoning (PO)

radiation effects (RE)

therapeutic use (TU)

toxicity (TO)

ultrastructure (UL)

urine (UR)

Amino Acids, Peptides, and Proteins [D12]
- Peptides [D12.644]
  - Peptide Fragments [D12.644.541]
    - Immunoglobulin Fragments [D12.644.541.500]
      - Immunoglobulin Fab Fragments [D12.644.541.500.650]
        
        Abciximab [D12.644.541.500.650.125]
        
        Certolizumab Pegol [D12.644.541.500.650.250]
        
        Immunoglobulin Variable Region [D12.644.541.500.650.500]
        
        Tuftsin [D12.644.541.500.650.750]

Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
  - Blood Proteins [D12.776.124]
    - Immunoproteins [D12.776.124.486]
      - Immunoglobulins [D12.776.124.486.485]
        
        Antibodies [D12.776.124.486.485.114]
        
        Antibodies, Monoclonal [D12.776.124.486.485.114.224]
        
        Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
        
        Abciximab [D12.776.124.486.485.114.224.060.125]
        
        Adalimumab [D12.776.124.486.485.114.224.060.250]
        
        Alemtuzumab [D12.776.124.486.485.114.224.060.313]
        
        Basiliximab [D12.776.124.486.485.114.224.060.344]
        
        Bevacizumab [D12.776.124.486.485.114.224.060.375]
        
        Brentuximab Vedotin [D12.776.124.486.485.114.224.060.438]
        
        Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
        
        Cetuximab [D12.776.124.486.485.114.224.060.750]
        
        Daclizumab [D12.776.124.486.485.114.224.060.766]
        
        Denosumab [D12.776.124.486.485.114.224.060.782]
        
        Gemtuzumab [D12.776.124.486.485.114.224.060.790]
        
        Inotuzumab Ozogamicin [D12.776.124.486.485.114.224.060.794]
        
        Ipilimumab [D12.776.124.486.485.114.224.060.798]
        
        Natalizumab [D12.776.124.486.485.114.224.060.813]
        
        Nivolumab [D12.776.124.486.485.114.224.060.829]
        
        Omalizumab [D12.776.124.486.485.114.224.060.844]
        
        Palivizumab [D12.776.124.486.485.114.224.060.860]
        
        Panitumumab [D12.776.124.486.485.114.224.060.864]
        
        Ranibizumab [D12.776.124.486.485.114.224.060.868]
        
        Trastuzumab [D12.776.124.486.485.114.224.060.875]
        
        Ustekinumab [D12.776.124.486.485.114.224.060.937]

Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
  - Blood Proteins [D12.776.124]
    - Immunoproteins [D12.776.124.486]
      - Immunoglobulins [D12.776.124.486.485]
        
        Immunoglobulin Fragments [D12.776.124.486.485.680]
        
        Immunoglobulin Fab Fragments [D12.776.124.486.485.680.650]
        
        Abciximab [D12.776.124.486.485.680.650.125]
        
        Certolizumab Pegol [D12.776.124.486.485.680.650.250]
        
        Immunoglobulin Variable Region [D12.776.124.486.485.680.650.500]
        
        Tuftsin [D12.776.124.486.485.680.650.750]

Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
  - Blood Proteins [D12.776.124]
    - Serum Globulins [D12.776.124.790]
      - Immunoglobulins [D12.776.124.790.651]
        
        Antibodies [D12.776.124.790.651.114]
        
        Antibodies, Monoclonal [D12.776.124.790.651.114.224]
        
        Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
        
        Abciximab [D12.776.124.790.651.114.224.060.125]
        
        Adalimumab [D12.776.124.790.651.114.224.060.250]
        
        Alemtuzumab [D12.776.124.790.651.114.224.060.375]
        
        Basiliximab [D12.776.124.790.651.114.224.060.407]
        
        Bevacizumab [D12.776.124.790.651.114.224.060.438]
        
        Brentuximab Vedotin [D12.776.124.790.651.114.224.060.469]
        
        Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
        
        Cetuximab [D12.776.124.790.651.114.224.060.750]
        
        Daclizumab [D12.776.124.790.651.114.224.060.766]
        
        Denosumab [D12.776.124.790.651.114.224.060.782]
        
        Gemtuzumab [D12.776.124.790.651.114.224.060.790]
        
        Inotuzumab Ozogamicin [D12.776.124.790.651.114.224.060.794]
        
        Ipilimumab [D12.776.124.790.651.114.224.060.798]
        
        Natalizumab [D12.776.124.790.651.114.224.060.813]
        
        Nivolumab [D12.776.124.790.651.114.224.060.829]
        
        Omalizumab [D12.776.124.790.651.114.224.060.844]
        
        Palivizumab [D12.776.124.790.651.114.224.060.860]
        
        Panitumumab [D12.776.124.790.651.114.224.060.864]
        
        Ranibizumab [D12.776.124.790.651.114.224.060.868]
        
        Trastuzumab [D12.776.124.790.651.114.224.060.875]
        
        Ustekinumab [D12.776.124.790.651.114.224.060.937]

Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
  - Blood Proteins [D12.776.124]
    - Serum Globulins [D12.776.124.790]
      - Immunoglobulins [D12.776.124.790.651]
        
        Immunoglobulin Fragments [D12.776.124.790.651.680]
        
        Immunoglobulin Fab Fragments [D12.776.124.790.651.680.650]
        
        Abciximab [D12.776.124.790.651.680.650.125]
        
        Certolizumab Pegol [D12.776.124.790.651.680.650.250]
        
        Immunoglobulin Variable Region [D12.776.124.790.651.680.650.500]
        
        Tuftsin [D12.776.124.790.651.680.650.750]

Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
  - Globulins [D12.776.377]
    - Serum Globulins [D12.776.377.715]
      - Immunoglobulins [D12.776.377.715.548]
        
        Antibodies [D12.776.377.715.548.114]
        
        Antibodies, Monoclonal [D12.776.377.715.548.114.224]
        
        Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
        
        Abciximab [D12.776.377.715.548.114.224.200.125]
        
        Adalimumab [D12.776.377.715.548.114.224.200.250]
        
        Alemtuzumab [D12.776.377.715.548.114.224.200.375]
        
        Basiliximab [D12.776.377.715.548.114.224.200.407]
        
        Bevacizumab [D12.776.377.715.548.114.224.200.438]
        
        Brentuximab Vedotin [D12.776.377.715.548.114.224.200.469]
        
        Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
        
        Cetuximab [D12.776.377.715.548.114.224.200.750]
        
        Daclizumab [D12.776.377.715.548.114.224.200.766]
        
        Denosumab [D12.776.377.715.548.114.224.200.782]
        
        Gemtuzumab [D12.776.377.715.548.114.224.200.790]
        
        Inotuzumab Ozogamicin [D12.776.377.715.548.114.224.200.794]
        
        Ipilimumab [D12.776.377.715.548.114.224.200.798]
        
        Natalizumab [D12.776.377.715.548.114.224.200.813]
        
        Nivolumab [D12.776.377.715.548.114.224.200.829]
        
        Omalizumab [D12.776.377.715.548.114.224.200.844]
        
        Palivizumab [D12.776.377.715.548.114.224.200.860]
        
        Panitumumab [D12.776.377.715.548.114.224.200.864]
        
        Ranibizumab [D12.776.377.715.548.114.224.200.868]
        
        Trastuzumab [D12.776.377.715.548.114.224.200.875]
        
        Ustekinumab [D12.776.377.715.548.114.224.200.937]

Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
  - Globulins [D12.776.377]
    - Serum Globulins [D12.776.377.715]
      - Immunoglobulins [D12.776.377.715.548]
        
        Immunoglobulin Fragments [D12.776.377.715.548.680]
        
        Immunoglobulin Fab Fragments [D12.776.377.715.548.680.650]
        
        Abciximab [D12.776.377.715.548.680.650.125]
        
        Certolizumab Pegol [D12.776.377.715.548.680.650.250]
        
        Immunoglobulin Variable Region [D12.776.377.715.548.680.650.500]
        
        Tuftsin [D12.776.377.715.548.680.650.750]

Abciximab Preferred

Concept UI: M0227707
Registry Number: X85G7936GV
Related Numbers: 143653-53-6
Scope Note: A Fab fragment of the chimeric monoclonal antibody 7E3 that binds to the glycoprotein IIb-IIIa receptor of human platelets, and blocks PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX, potently inhibiting PLATELET AGGREGATION. It is used in treatment of refractory unstable angina, and for prevention of ischemic complications in patients undergoing percutaneous coronary procedures such as ANGIOPLASTY; ATHERECTOMY; or stenting.
Terms: Abciximab Preferred Term
Term UI T000938715
Date01/05/2018
LexicalTag NON
ThesaurusID USAN (1994); c7E3 Fab
Term UI T257710
LexicalTag ABB
ThesaurusID NLM (1994); Chimeric 7E3 Fab
Term UI T000938716
Date01/05/2018
LexicalTag ABX
ThesaurusID NLM (2019)

ReoPro Narrower

Clotinab Narrower

CentoRx Narrower

Abciximab MeSH Descriptor Data 2023